INTRANASAL CALCITONIN IN THE TREATMENT OF OSTEOPENIA AND OSTEOPOROSIS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目及 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 本研究的具体目的是比较经鼻给予降钙素加钙和维生素D补充剂治疗与安慰剂加钙和维生素D补充剂治疗对诊断为IBD和腰椎骨密度低（腰椎BMD比相同年龄和性别的健康受试者低1个标准差或更多）的患者的腰椎骨密度的影响。 主要终点是治疗开始后18个月时通过双能X线吸收测定法（DXA）测量的腰椎BMD。我们选择腰椎骨密度作为主要结果变量，因为腰椎是骨小梁的代表。 松质骨具有最快的周转，因此最准确和一致地反映骨矿物质质量的快速变化。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Specific aim of the study is to compare the effect of treatment with nasally administered calcitonin plus calcium and vitamin D supplementation to that of treatment with placebo plus calcium and vitamin D supplementation on the lumbar bone mineral density of patients with the diagnosis of IBD and low lumbar bone mineral density (lumbar BMD 1 standard deviation or more below that of a healthy subject with the same age and sex). The primary endpoint will be lumbar BMD at 18 months after initiation of the treatment, measured by dual energy x-ray absorptiometry (DXA). We have selected lumbar spine BMD as the primary outcome variable because the lumbar spine is representative of trabecular bone. Trabecular bone has the most rapid turnover, and therefore reflects rapid changes in bone mineral mass most accurately and consistently.